DUBLIN, Ireland — Perrigo Co. and Allergan plc have rolled out guaifenesin 1,200-mg and dextromethorphan HBr 60-mg extended-release tablets, a combination expectorant and cough suppressant.

The companies said Tuesday that the product marks the first over-the-counter store-brand equivalent to Mucinex DM 1,200-mg ER tablets from Reckitt Benckiser (RB) for retail and wholesale customers.

First shipments of the new store-branded products have commenced. The products are packaged and marketed as store brands or retailer ‘own label’ brands and provide consumers a high-quality, value alternative, according to Perrigo.

Indicated to control coughs and to break up mucus, making coughs more productive, Mucinex DM 1,200-mg ER tablets totaled sales of about $108 million through food, drug and mass merchants during the last 12 months, Perrigo reported.

“This is another great example of the Perrigo and Allergan teams continuing to leverage their unique capabilities in providing U.S. consumers greater savings and access to key new store-brand OTC products,” stated Perrigo chief executive officer John Hendrickson. “These new store-brand products, which are equivalent to the Mucinex brand, are an important offering to our customers as they deliver the first high-quality, value alternative available in the marketplace.

“Allergan has been an excellent partner in developing this range of new store brand guaifenesin ER products,” he added, “and we look forward to launching the remaining Mucinex equivalent products for the store-brand market throughout the balance of this year.”

In late March, Perrigo and Allergan released 1,200-mg guaifenesin ER tablets, a generic equivalent to Mucinex ER tablets, while in January they launched guaifenesin 600-mg and pseudoephedrine HCl 60-mg ER tablets, a store-brand alternative to Mucinex D.

“Today’s launch adds to the record of success we have had in bringing together Allergan’s leadership in generic product development with Perrigo’s strength in marketing OTC and store-brand products to deliver high-quality, affordable medicines for patients around the world,” commented Robert Stewart, executive vice president and president of generics and global operations at Allergan. “We look forward to our continued efforts to bring additional formulations that are equivalent to the Mucinex family of products forward for the patients and customers that we serve.”